India, May 6 -- Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company, on Wednesday announced the first release of sub-score data from the eosinophilic esophagitis histologic scoring system (EoEHSS) used in the Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI in treating eosinophilic esophagitis.
Eosinophilic esophagitis (EoE) is a chronic immune disease caused by white blood cells migrating and getting stuck in the esophagus, causing pain and obstacles to swallowing. It is estimated that over 450,000 people live with the disease in the U.S. alone.
EP-104GI is being developed by Eupraxia for the treatment of EoE, and the EoEHSS is used to evaluate tissue damage in the esophagus due to EoE. The system utiliz...